Brown-Forman plays down Cannabis, GLP-1 drugs impact on US spirits.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      BROWN-Forman Corp. BFB
    • Abstract:
      Brown-Forman, a major US spirits company, has downplayed the impact of cannabis consumption and GLP-1 weight-loss drugs on the decline in US spirits sales. The CEO of Brown-Forman stated that these factors, along with behavioral changes of Gen Z, are long-term challenges for the spirits industry but do not currently affect consumer behavior or the state of the spirits business in the US. The company reported a 4% decrease in US net sales in its 2023-2024 fiscal year, attributing it to factors such as supply chain issues and changes in distributor and retail ordering patterns. Brown-Forman expects trends to improve in the fall or winter. [Extracted from the article]
    • Abstract:
      Copyright of Aroq - Just-Drinks.com (Global News) is the property of GlobalData UK Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)